ImmunoGen, Inc. (IMGN): Price and Financial Metrics


ImmunoGen, Inc. (IMGN): $4.75

0.04 (+0.85%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add IMGN to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

IMGN POWR Grades

  • IMGN scores best on the Value dimension, with a Value rank ahead of 62.52% of US stocks.
  • IMGN's strongest trending metric is Quality; it's been moving up over the last 177 days.
  • IMGN ranks lowest in Momentum; there it ranks in the 5th percentile.

IMGN Stock Summary

  • With a price/sales ratio of 10.88, IMMUNOGEN INC has a higher such ratio than 89.3% of stocks in our set.
  • In terms of twelve month growth in earnings before interest and taxes, IMMUNOGEN INC is reporting a growth rate of 184.54%; that's higher than 91.57% of US stocks.
  • As for revenue growth, note that IMGN's revenue has grown -25.11% over the past 12 months; that beats the revenue growth of just 7.44% of US companies in our set.
  • Stocks that are quantitatively similar to IMGN, based on their financial statements, market capitalization, and price volatility, are IMRX, PRQR, VBLT, INO, and OGEN.
  • IMGN's SEC filings can be seen here. And to visit IMMUNOGEN INC's official web site, go to www.immunogen.com.

IMGN Valuation Summary

  • In comparison to the median Healthcare stock, IMGN's price/sales ratio is 426.83% higher, now standing at 10.8.
  • Over the past 243 months, IMGN's price/earnings ratio has gone up 2.7.

Below are key valuation metrics over time for IMGN.

Stock Date P/S P/B P/E EV/EBIT
IMGN 2023-01-20 10.8 5.8 -5.1 -3.7
IMGN 2023-01-19 10.3 5.5 -4.9 -3.4
IMGN 2023-01-18 10.3 5.5 -4.9 -3.4
IMGN 2023-01-17 10.4 5.6 -4.9 -3.5
IMGN 2023-01-13 10.5 5.6 -5.0 -3.5
IMGN 2023-01-12 10.9 5.9 -5.2 -3.7

IMGN Growth Metrics

    The 4 year cash and equivalents growth rate now stands at 95.39%.
  • Its 3 year cash and equivalents growth rate is now at 61.86%.
  • Its year over year cash and equivalents growth rate is now at 54.58%.
Over the past 15 months, IMGN's revenue has gone down $41,034,000.

The table below shows IMGN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 95.607 -215.477 -201.093
2022-06-30 89.442 -186.309 -160.677
2022-03-31 92.228 -166.197 -129.397
2021-12-31 69.856 -169.416 -139.303
2021-09-30 127.662 -115.007 -70.743
2021-06-30 136.641 -110.612 -55.778

IMGN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • IMGN has a Quality Grade of C, ranking ahead of 34.67% of graded US stocks.
  • IMGN's asset turnover comes in at 0.393 -- ranking 121st of 682 Pharmaceutical Products stocks.
  • TARO, HTBX, and ENTA are the stocks whose asset turnover ratios are most correlated with IMGN.

The table below shows IMGN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-09-30 0.393 1 1.722
2021-06-30 0.437 1 1.612
2021-03-31 0.442 1 1.694
2020-12-31 0.452 1 2.339
2020-09-30 0.347 1 9.437
2020-06-30 0.327 1 10.967

IMGN Price Target

For more insight on analysts targets of IMGN, see our IMGN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $9.79 Average Broker Recommendation 1.55 (Moderate Buy)

IMGN Stock Price Chart Interactive Chart >

Price chart for IMGN

IMGN Price/Volume Stats

Current price $4.75 52-week high $6.63
Prev. close $4.71 52-week low $3.10
Day low $4.70 Volume 1,684,800
Day high $4.87 Avg. volume 3,170,044
50-day MA $4.89 Dividend yield N/A
200-day MA $4.96 Market Cap 1.05B

ImmunoGen, Inc. (IMGN) Company Bio


Immunogen develops targeted anticancer therapeutics. The Company's ADC technology uses tumor-targeting antibodies to deliver an ImmunoGen cell-killing agent specifically to cancer cells. The company was founded in 1981 and is based in Waltham, Massachusetts.


IMGN Latest News Stream


Event/Time News Detail
Loading, please wait...

IMGN Latest Social Stream


Loading social stream, please wait...

View Full IMGN Social Stream

Latest IMGN News From Around the Web

Below are the latest news stories about IMMUNOGEN INC that investors may wish to consider to help them evaluate IMGN as an investment opportunity.

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., January 04, 2023--ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on December 29, 2022, and in connection with the previously announced appointment of Michael J. Vasconcelles, MD as ImmunoGen’s Executive Vice President, Research, Development, and Medical Affairs, the compensation committee of the Company’s Board of Directors (the "Compensation Committee") approved grants of non-qu

Yahoo | January 4, 2023

ImmunoGen Appoints Michael Vasconcelles, MD, as Executive Vice President, Research, Development, and Medical Affairs

WALTHAM, Mass., January 04, 2023--ImmunoGen Appoints Michael Vasconcelles, MD, as Executive Vice President, Research, Development, and Medical Affairs

Yahoo | January 4, 2023

Aurinia (AUPH) Soars 37.5%: Is Further Upside Left in the Stock?

Aurinia (AUPH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Yahoo | January 4, 2023

Need To Know: The Consensus Just Cut Its ImmunoGen, Inc. (NASDAQ:IMGN) Estimates For 2023

Today is shaping up negative for ImmunoGen, Inc. ( NASDAQ:IMGN ) shareholders, with the analysts delivering a...

Yahoo | January 3, 2023

Company News for Dec 30, 2022

Companies in The News Are: IMGN, TGTX, TSLA, MSFT

Yahoo | December 30, 2022

Read More 'IMGN' Stories Here

IMGN Price Returns

1-mo -7.95%
3-mo -21.62%
6-mo 4.86%
1-year -9.35%
3-year -5.28%
5-year -43.38%
YTD -4.23%
2022 -33.15%
2021 15.04%
2020 26.35%
2019 6.35%
2018 -25.12%

Continue Researching IMGN

Want to see what other sources are saying about ImmunoGen Inc's financials and stock price? Try the links below:

ImmunoGen Inc (IMGN) Stock Price | Nasdaq
ImmunoGen Inc (IMGN) Stock Quote, History and News - Yahoo Finance
ImmunoGen Inc (IMGN) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.727 seconds.